Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational

Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors

NCT01351727
View directory record Official record
Conditions
Epileptic Seizures
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
65 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

NCT01191086
View directory record Official record
Conditions
Epilepsy
Interventions
USL255
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

NCT03054961
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Near-infrared spectroscopy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting

NCT00013455
View directory record Official record
Conditions
Hearing Loss
Interventions
Hearing
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 23, 2026, 6:14 AM EDT
Withdrawn Not applicable Interventional

Remote EEG Device for Identification of Risk for Neonatal Seizures

NCT05239585
View directory record Official record
Conditions
Neonatal Encephalopathy
Interventions
Epilog device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 30 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

NCT02849626
View directory record Official record
Conditions
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
29
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 23, 2026, 6:14 AM EDT
Suspended Not applicable Interventional

Glioblastoma Remote Monitoring and Care - Research Protocol

NCT06129760
View directory record Official record
Conditions
Glioblastoma, Venous Thromboembolism, Seizures
Interventions
Apple Watch
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Photosensitivity Proof of Concept Trial

NCT00894010
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
carbamazepine 400mg, levetiracetam 1000mg
Drug
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 23, 2026, 6:14 AM EDT
Withdrawn Phase 1 Interventional

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

NCT03895658
View directory record Official record
Conditions
Unipolar Depression
Interventions
MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

NCT00007670
View directory record Official record
Conditions
Seizures
Interventions
Carbamazepine, Gabapentin, Lamotrigine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

NCT01702623
View directory record Official record
Conditions
Seizures
Interventions
Oxcarbazepine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Development of a Practical, Minimally Invasive Seizure Gauge

NCT03745118
View directory record Official record
Conditions
Epilepsy
Interventions
EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
66
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Room Temperature Atomic Magnetrode System for Telemetry of Epileptic Seizures

NCT04515316
View directory record Official record
Conditions
Epilepsy
Interventions
OPM sensors, SQUID sensors
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Sleep Spindles and Memory in Rolandic Epilepsy

NCT04569708
View directory record Official record
Conditions
Rolandic Epilepsy, Rolandic Epilepsy, Benign, Centrotemporal Epilepsy, Centrotemporal; EEG Spikes, Epilepsy of Childhood, Epilepsy; Seizure, Epilepsy
Interventions
Closed loop auditory stimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
96
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

NCT03892798
View directory record Official record
Conditions
Autism Spectrum Disorder, Movement Disorders, Seizures, Dystonia, NEDAMSS
Interventions
No interventions are planned
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Months to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779
View directory record Official record
Conditions
Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions
Pre-visit prep, usual care + exome seq
Behavioral · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Not applicable Interventional

Effects of Recorded Music on Clinical and EEG Seizure Activity

NCT05289934
View directory record Official record
Conditions
Epilepsy
Interventions
Music Stimuli
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
4 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050934
View directory record Official record
Conditions
Epilepsy, Epilepsies, Partial
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 3 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

NCT02694094
View directory record Official record
Conditions
Hypercholesterolemia, Carotid Intimal Medial Thickness 1, Seizure, Epilepsy, Cardiovascular Disease, Cerebrovascular Disease, Heart Disease, Coronary Disease
Interventions
Modified Atkins or Ketogenic Diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 6:14 AM EDT